(CercleFinance.com) – GlaxoSmithKline gained nearly 3% in London, benefiting from an analysis by Berenberg which raised its price target on the stock from 1,630 to 1,700 pence, while maintaining its buy recommendation on the stock. pharmaceutical laboratory.
In his research note, the German broker returns to the particular challenge that he sees as the conclusions of the phase III clinical study in the respiratory syncytial virus, expected during the first half of the year.
“These are the most important results to be unveiled by the group in 2022”, warns the intermediary, who evokes a “significant” business opportunity and a crucial meeting from the point of view of investors.
‘We believe that GSK is on track to succeed,’ he nevertheless reassures in his note.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
